Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases: 2019-2025

Historic Operating Leases for Enanta Pharmaceuticals (ENTA) over the last 6 years, with Sep 2025 value amounting to $54.8 million.

  • Enanta Pharmaceuticals' Operating Leases rose 1.51% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 1.51%. This contributed to the annual value of $54.8 million for FY2025, which is 1.51% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Operating Leases stood at $54.8 million for Q3 2025, which was down 1.62% from $55.7 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Leases peaked at $56.5 million during Q1 2025, and registered a low of $1.1 million during Q3 2021.
  • Its 3-year average for Operating Leases is $41.5 million, with a median of $48.1 million in 2024.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Operating Leases slumped by 70.66% in 2021, and later skyrocketed by 1,886.86% in 2022.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Leases (Quarterly) stood at $16.0 million in 2021, then spiked by 36.98% to $21.9 million in 2022, then dropped by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then increased by 1.51% to $54.8 million in 2025.
  • Its Operating Leases stands at $54.8 million for Q3 2025, versus $55.7 million for Q2 2025 and $56.5 million for Q1 2025.